{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:22:25Z","timestamp":1740122545146,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02956-5","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T21:14:21Z","timestamp":1709327661000},"page":"630-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review"],"prefix":"10.1007","volume":"57","author":[{"given":"L.","family":"Al-Tourah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mithoowani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-0589","authenticated-orcid":false,"given":"Rick","family":"Ikesaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"4","key":"2956_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458\u2013464. https:\/\/doi.org\/10.1001\/archinte.166.4.458","journal-title":"Arch Intern Med"},{"issue":"6","key":"2956_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809\u2013815. https:\/\/doi.org\/10.1001\/archinte.160.6.809","journal-title":"Arch Intern Med"},{"issue":"Suppl 4","key":"2956_CR3","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0049-3848(09)70137-9","volume":"123","author":"R Sud","year":"2009","unstructured":"Sud R, Khorana AA (2009) Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 123(Suppl 4):S18\u2013S21. https:\/\/doi.org\/10.1016\/S0049-3848(09)70137-9","journal-title":"Thromb Res"},{"issue":"6","key":"2956_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490\u2013493. https:\/\/doi.org\/10.1016\/j.thromres.2009.12.023Epub 2010 Jan 25. PMID: 20097409; PMCID: PMC2878879","journal-title":"Thromb Res"},{"issue":"2","key":"2956_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"issue":"12","key":"2956_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","volume":"136","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, Bosch FTM, Young AM et al (2020) Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 136(12):1433\u20131441. https:\/\/doi.org\/10.1182\/blood.2020005819","journal-title":"Blood"},{"key":"2956_CR7","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1002\/onco.13596","volume":"26","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G (2021) Update on guidelines for the management of Cancer-Associated thrombosis. Oncol 26:e24\u2013e40. https:\/\/doi.org\/10.1002\/onco.13596","journal-title":"Oncol"},{"issue":"7","key":"2956_CR8","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Mu\u00f1oz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-Garc\u00eda LA, Bounameaux H, Pabinger I, Douketis J, International Initiative on Thrombosis and Cancer (ITAC) advisory panel (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7PMID: 35772465; PMCID: PMC9236567","journal-title":"Lancet Oncol"},{"issue":"1","key":"2956_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12959-022-00399-7","volume":"20","author":"T Rungjirajittranon","year":"2022","unstructured":"Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B (2022) Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thromb J 20(1):41. https:\/\/doi.org\/10.1186\/s12959-022-00399-7","journal-title":"Thromb J"},{"issue":"7","key":"2956_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of Cancer-Associated venous thromboembolism. N Engl J Med 378(7):615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"issue":"20","key":"2956_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor xa inhibitor with low Molecular Weight Heparin in patients with Cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","journal-title":"J Clin Oncol"},{"issue":"9","key":"2956_CR12","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1055\/s-0038-1668523","volume":"118","author":"G Agnelli","year":"2018","unstructured":"Agnelli G, Becattini C, Bauersachs R et al (2018) Apixaban versus Dalteparin for the treatment of Acute venous thromboembolism in patients with Cancer: the Caravaggio Study. Thromb Haemost 118(9):1668\u20131678. https:\/\/doi.org\/10.1055\/s-0038-1668523","journal-title":"Thromb Haemost"},{"issue":"2","key":"2956_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421. https:\/\/doi.org\/10.1111\/jth.14662","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2956_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/cam4.1997","volume":"8","author":"M S\u00f8gaard","year":"2019","unstructured":"S\u00f8gaard M, Nielsen PB, Skj\u00f8th F, Kjaeldgaard JN, Larsen TB (2019) Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: a nationwide cohort study. Cancer Med 8(3):1044\u20131053. https:\/\/doi.org\/10.1002\/cam4.1997Epub 2019 Feb 14. PMID: 30767432; PMCID: PMC6434207","journal-title":"Cancer Med"},{"issue":"4","key":"2956_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","volume":"136","author":"N De Crem","year":"2015","unstructured":"De Crem N, Peerlinck K, Vanassche T et al (2015) Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 136(4):749\u2013753. https:\/\/doi.org\/10.1016\/j.thromres.2015.07.030","journal-title":"Thromb Res"},{"issue":"2","key":"2956_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bjh.13583","volume":"173","author":"M Ferreira","year":"2016","unstructured":"Ferreira M, Barsam S, Patel JP et al (2016) Heavy menstrual bleeding on rivaroxaban. Br J Haematol 173(2):314\u2013315. https:\/\/doi.org\/10.1111\/bjh.13583","journal-title":"Br J Haematol"},{"key":"2956_CR17","doi-asserted-by":"publisher","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med. ;21(11):1539-58. https:\/\/doi.org\/10.1002\/sim.1186. PMID: 12111919","DOI":"10.1002\/sim.1186"},{"issue":"5","key":"2956_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v049.i05","volume":"49","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2012) Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 49(5):1\u201315","journal-title":"J Stat Softw"},{"issue":"4","key":"2956_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2956_CR20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2956_CR21","doi-asserted-by":"publisher","first-page":"e12604","DOI":"10.1002\/rth2.12604","volume":"5","author":"A Maraveyas","year":"2021","unstructured":"Maraveyas A, Beyer-Westendorf J, Lee AY et al (2021) Cancer-Associated ThrOmboSIs - Patient-reported OutcoMes with RivarOxaban (COSIMO) - baseline characteristics and clinical outcomes. Res Pract Thromb Haemost 5(8):e12604 Published 2021 Nov 30. https:\/\/doi.org\/10.1002\/rth2.12604","journal-title":"Res Pract Thromb Haemost"},{"key":"2956_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","volume":"185","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, van Es N, Kraaijpoel N et al (2020) Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study [published correction appears in Thromb Res. 2020;191:156\u2013159]. Thromb Res 185:13\u201319. https:\/\/doi.org\/10.1016\/j.thromres.2019.11.007","journal-title":"Thromb Res"},{"issue":"1","key":"2956_CR23","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37\u2013e46. https:\/\/doi.org\/10.1016\/S2352-3026(14)70018-3","journal-title":"Lancet Haematol"},{"issue":"5","key":"2956_CR24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1097\/IGC.0000000000000972","volume":"27","author":"MJP Renni","year":"2017","unstructured":"Renni MJP, Araujo MLC, Jr, Trugilho I, Bergmann A, de Morais E, Coura CP (2017) Rivaroxaban used in the treatment patients with gynecologic Cancer and venous thromboembolism: the experience of Instituto Nacional De C\u00e2ncer-Rio De Janeiro, Brazil. Int J Gynecol Cancer 27(5):1042\u20131045. https:\/\/doi.org\/10.1097\/IGC.0000000000000972","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2956_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/rth2.12215","volume":"3","author":"GA Soff","year":"2019","unstructured":"Soff GA, Mones J, Wilkins C et al (2019) Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost 3(3):349\u2013356 Published 2019 May 24. https:\/\/doi.org\/10.1002\/rth2.12215","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2956_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1055\/s-0037-1607436","volume":"44","author":"V Russo","year":"2018","unstructured":"Russo V, Rago A, Papa AA et al (2018) Use of Non-vitamin K antagonist oral anticoagulants in Atrial Fibrillation patients with malignancy: clinical practice experience in a single Institution and Literature Review. Semin Thromb Hemost 44(4):370\u2013376. https:\/\/doi.org\/10.1055\/s-0037-1607436","journal-title":"Semin Thromb Hemost"},{"key":"2956_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.07.138","volume":"269","author":"MC Vedovati","year":"2018","unstructured":"Vedovati MC, Giustozzi M, Verdecchia P et al (2018) Patients with cancer and atrial fibrillation treated with DOACs: a prospective cohort study. Int J Cardiol 269:152\u2013157. https:\/\/doi.org\/10.1016\/j.ijcard.2018.07.138","journal-title":"Int J Cardiol"},{"issue":"1","key":"2956_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","volume":"15","author":"C Frere","year":"2022","unstructured":"Frere C, Farge D, Schrag D, Prata PH, Connors JM (2022) Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 15(1):69. https:\/\/doi.org\/10.1186\/s13045-022-01289-1. Published 2022 May 21","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2956_CR29","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.3802\/jgo.2022.33.e62","volume":"33","author":"S Odajima","year":"2022","unstructured":"Odajima S, Seki T, Kato S, Tomita K, Shoburu Y, Suzuki E, Takenaka M, Saito M, Takano H, Yamada K, Okamoto A (2022) Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data. J Gynecol Oncol 33(5):e62 Epub 2022 Jun 7. PMID: 35712973; PMCID: PMC9428303","journal-title":"J Gynecol Oncol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02956-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02956-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02956-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:08:50Z","timestamp":1713442130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02956-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02956-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"6 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}